Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Morning Bell 1 May

Grady Wulff
May 1, 2024

Morning Bell 30 April

Grady Wulff
April 30, 2024

Morning Bell 29 April

Grady Wulff
April 29, 2024

Morning Bell 26 April

Sam Kanaan
April 26, 2024

Morning Bell 24 April

Grady Wulff
April 24, 2024

Morning Bell 23 April

Sam Kanaan
April 23, 2024

Morning Bell 22 April

Grady Wulff
April 22, 2024

Morning Bell 19 April

Sam Kanaan
April 19, 2024

Morning Bell 18 April

Grady Wulff
April 18, 2024

Morning Bell 17 April

Grady Wulff
April 17, 2024